Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Cinclus Pharma Holding AB ( (SE:CINPHA) ).
Cinclus Pharma has announced the recruitment of Magnus Christensen as their new CFO, following the departure of Maria Engström. Christensen, who brings extensive experience from his previous role at Medivir, will join the company in spring 2026. In the interim, Patrik Norgren will serve as CFO to ensure a smooth transition. This leadership change comes as Cinclus Pharma progresses its drug candidate linaprazan glurate through Phase III trials, aiming for global commercialization and addressing the unmet needs in GERD treatment.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and upper gastrointestinal tract disorders. Its leading drug candidate, linaprazan glurate, aims to treat gastroesophageal reflux disease (GERD) more effectively than current treatments. The company is advancing linaprazan glurate through Phase III studies, targeting a significant market need in the US and EU.
Average Trading Volume: 58,123
Technical Sentiment Signal: Buy
Current Market Cap: SEK791.1M
For an in-depth examination of CINPHA stock, go to TipRanks’ Overview page.